Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis
Authors
Keywords
-
Journal
Neurotherapeutics
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-26
DOI
10.1007/s13311-021-01006-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives
- (2020) Etienne Crickx et al. KIDNEY INTERNATIONAL
- B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis
- (2020) Young Gi Min et al. Experimental Neurobiology
- Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules
- (2020) Benjamin P. Trewin et al. Multiple Sclerosis and Related Disorders
- Tailoring B cell depletion therapy in MS according to memory B cell monitoring
- (2020) Giovanni Novi et al. Neurology-Neuroimmunology & Neuroinflammation
- Myasthenia gravis
- (2019) Nils Erik Gilhus et al. Nature Reviews Disease Primers
- Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis
- (2019) Sisi Jing et al. JOURNAL OF NEUROIMMUNOLOGY
- Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases
- (2019) Pierre Durozard et al. ANNALS OF NEUROLOGY
- Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis
- (2019) Jun Lu et al. MUSCLE & NERVE
- Measuring Clinical Treatment Response in Myasthenia Gravis
- (2018) Carolina Barnett et al. NEUROLOGIC CLINICS
- Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab
- (2018) Fiona Chan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Immunotherapy in myasthenia gravis in the era of biologics
- (2018) Marinos C. Dalakas Nature Reviews Neurology
- Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis
- (2017) Sisi Jing et al. JOURNAL OF NEUROIMMUNOLOGY
- Rituximab treatment of myasthenia gravis: A systematic review
- (2017) Rup Tandan et al. MUSCLE & NERVE
- Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients
- (2017) Vadim Afanasiev et al. NEUROMUSCULAR DISORDERS
- Memory B cell resurgence requires repeated rituximab in myasthenia gravis
- (2017) Kohei Muto et al. NEUROMUSCULAR DISORDERS
- Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis
- (2017) Kimberly R. Robeson et al. JAMA Neurology
- B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis
- (2017) Rita A. Moura et al. PLoS One
- Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis
- (2016) Christine Lebrun et al. JOURNAL OF NEUROIMMUNOLOGY
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
- (2015) Su-Hyun Kim et al. JAMA Neurology
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
- (2013) Su-Hyun Kim et al. JAMA Neurology
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
- (2011) Su-Hyun Kim ARCHIVES OF NEUROLOGY
- Use and monitoring of low dose rituximab in myasthenia gravis
- (2010) S. Blum et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Successful treatment of refractory generalized myasthenia gravis with rituximab
- (2008) C. Lebrun et al. EUROPEAN JOURNAL OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search